Healthcare / BiotechnologyStockholm
$1.07
-0.05 (-4.29%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-129.8M · quality 51.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
8/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$147M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-60.6%
↓Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2025 · 4 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
—
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-169.8M · FCF —
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | — | — | $130000.00 | $546000.00 | $454000.00 | $253000.00 |
| Net Income | $-169.8M | $-169.8M | $-151.8M | $-116.1M | $-103.5M | — |
| EBITDA | $-163.3M | $-163.3M | $-140.9M | $-111.2M | $-98.9M | — |
| EPS | -1.50 | -1.50 | -1.60 | -1.49 | -1.36 | — |
| Gross Margin | — | — | -2753.8% | -565.6% | -869.8% | — |
| Operating Margin | — | — | -113287.7% | -21217.2% | -25316.3% | — |
| Net Margin | — | — | -116807.7% | -21258.8% | -22801.1% | — |
| Balance Sheet | ||||||
| Debt/Equity | — | — | 0.21 | 0.09 | — | — |
| Current Ratio | 4.83 | 4.83 | — | — | — | — |
| Cash Flow | ||||||
| Free Cash Flow | — | — | $-137.2M | $-122.4M | $-127.9M | $-113.7M |
| Returns | ||||||
| ROE | -60.6% | -60.6% | -104.1% | -68.5% | -48.3% | — |
| Valuation | ||||||
| P/B | 0.43 | 0.43 | 9.81 | 4.35 | 5.33 | — |
| Growth & Yield | ||||||
| Revenue Growth | — | — | -76.2% | 20.3% | 79.4% | — |
| EPS Growth | 6.3% | 6.3% | -7.2% | -9.7% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-88.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.60 → -1.50
Residual
-88.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.